This text is a result of machine translation.
Press secretary of the Russian President: Russia's special military action against Ukraine continues
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Yesterday 12:13 PM
Xuanya International: orange power has reduced 1.09% of its shares in total
Abnormal lifting of titanium dioxide plate
Topbond shares: the wholly-owned subsidiary plans to invest 5 billion yuan in the construction of lithium battery project
Longbai group: it plans to invest 3.5 billion yuan in the integration project of lithium ion battery cathode materials
Longbai group: all directors, supervisors and senior executives promise not to reduce their holdings of the company's shares within a certain period of time
Ziguang Guowei: the net profit in the third quarter increased by 105.87% year-on-year, and Gao Yi reduced his holdings
More than 90 billion yuan of funds participated in the "innovation" of five selected tier stocks
Fledgling Players, Top-selling Products: China's Smart Home Industry in 2022
Jun 23, 2022 11:14 AM